Scholarlink

<p>Homeobox A9 promoter methylation (<i>HOXA9</i>) has been reported as a biomarker for early lung adenocarcinoma patients’ prognosis. We aim to evaluate its prognostic value, regardless of disease stage. Using droplet digital PCR, we measured <i>HOXA9</i> methylation in a cohort comprising 161 Brazilian patients. Low <i>HOXA9</i> methylation was associated with higher cancer-specific survival but showed no significance after adjustment for clinical covariates. While low <i>HOXA</i>9 methylation was associated with earlier stages, no survival association was observed in this subset of patients. Overall, <i>HOXA9</i> promoter methylation is not an independent prognostic biomarker of cancer-specific survival in Brazilian lung adenocarcinomas patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

HOXA9 methylation is not associated with survival in Brazilian patients with lung adenocarcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年2月17日

查看全文
  • Anna Luiza Silva Almeida Vicente,
  • Fabiana Aparecida de Souza Santos,
  • Welinton Yoshio Hirai,
  • Delphine Lissa,
  • Rodrigo de Oliveira Cavagna,
  • Aline Larissa Virginio da Silva,
  • Mariana Bisarro dos Reis,
  • Eduardo Caetano Albino da Silva,
  • Flávio Augusto Ferreira da Silva,
  • Josiane Dias Mourão,
  • Pedro De Marchi,
  • Ana Carolina de Carvalho,
  • Letícia Ferro Leal,
  • Rui Manuel Reis

摘要

Homeobox A9 promoter methylation (HOXA9) has been reported as a biomarker for early lung adenocarcinoma patients’ prognosis. We aim to evaluate its prognostic value, regardless of disease stage. Using droplet digital PCR, we measured HOXA9 methylation in a cohort comprising 161 Brazilian patients. Low HOXA9 methylation was associated with higher cancer-specific survival but showed no significance after adjustment for clinical covariates. While low HOXA9 methylation was associated with earlier stages, no survival association was observed in this subset of patients. Overall, HOXA9 promoter methylation is not an independent prognostic biomarker of cancer-specific survival in Brazilian lung adenocarcinomas patients.